
At Neurosalience we develop a tool for early detection of dementia from MRI scans (including low resolution), with potential possibility of expanding to CT scans, providing an opportunity to decrease further patient related costs and increase the quality of life of patients.

At Neurosalience we develop a tool for early detection of dementia from MRI scans (including low resolution), with potential possibility of expanding to CT scans, providing an opportunity to decrease further patient related costs and increase the quality of life of patients.
Product: Interpretable ML tool for early detection of dementia from structural MRI (extendable to CT), including low-resolution MRI
Headquarters: London, United Kingdom
Founders: Ksenia Sokolova and Michael Sokolovs
Regulatory / validation: Product pending classification as a Class II(a) medical device and undergoing clinical trials
Funding: Grant-stage funding recorded (Prototron); total disclosed funding USD 10,000 (recorded)
Early detection and risk assessment of dementia / neurodegenerative disease from medical imaging
Health / Medtech
10000.00 USD
Recorded as a grant-stage funding event led by Prototron
“Received grant funding from Prototron”